Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06381648 · ClinicalTrials.gov registry record
Detecting Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma (LyMIC)
A clinical trial of Cholangiocarcinoma and Cholangiocarcinoma, Intrahepatic, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- 230
- Enrollment target
- 4
- Study locations
NCT06381648 is a study of Cholangiocarcinoma and Cholangiocarcinoma, Intrahepatic that has completed, run by City of Hope Medical Center. The registered enrollment target is 230 participants, below the 382-participant average among 60 other Cholangiocarcinoma trials with a reported enrollment target (40% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT06381648, a study of Cholangiocarcinoma and Cholangiocarcinoma, Intrahepatic, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- 230 participants
- Enrollment target
- 4
- Study locations
Study Summary
Lymph node metastasis (LNM) is a major prognostic factor in intrahepatic cholangiocarcinoma (ICC), and accurate preoperative prediction of the presence or absence of LNM has significant clinical implications in determining treatment strategy. Despite this, there are currently no reliable biomarkers established to detect LNM in ICC. This study seeks to develop a liquid biopsy assay that can accurately detect LNM before treatment in ICC patients.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST LyMIC (Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma)
Study Locations (4)
Other
- Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University - Fukuoka
- Department of Surgery, Tokushima University - Tokushima
California
- City of Hope Medical Center - Duarte
Sapporo
- Department of Gastroenterological Surgery I, Graduate School of Medicine, Hokkaido University - Hokkaido
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 230 participants |
| Start Date | 2023-04-15 |
| Est. Completion | 2025-07-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06381648
The ClinicalTrials.gov registry entry for NCT06381648 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 230 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 382-participant average among 60 other Cholangiocarcinoma trials with a reported enrollment target (40% lower). The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Cholangiocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which LyMIC (Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma) is the first listed.
NCT06381648 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Other, California, Sapporo.
Frequently Asked Questions
What is clinical trial NCT06381648 about?
NCT06381648 is a clinical study titled "Detecting Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma (LyMIC)". Lymph node metastasis (LNM) is a major prognostic factor in intrahepatic cholangiocarcinoma (ICC), and accurate preoperative prediction of the presence or absence of LNM has significant clinical implications in determining treatment strategy. Despite this, there are currently no reliable biomarkers ...
What is the current status of trial NCT06381648?
This trial is currently completed. The enrollment target is 230 participants. The study started on 2023-04-15. Estimated completion is 2025-07-01.
What conditions does trial NCT06381648 study?
This clinical trial studies the following conditions: Cholangiocarcinoma, Cholangiocarcinoma, Intrahepatic, Cholangiocarcinoma Resectable, Cholangiocarcinoma; Liver.
What interventions are being tested in trial NCT06381648?
The interventions under investigation include: LyMIC (Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06381648?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06381648 being conducted?
This trial has 4 study locations across California, Sapporo. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cholangiocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)
RECRUITING · Phase 2
-
Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer
RECRUITING
-
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
RECRUITING · Phase 4
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
RECRUITING · Phase 2
-
Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.